Literature DB >> 16769711

Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants.

E S Shinwell1, L Lerner-Geva, A Lusky, B Reichman.   

Abstract

OBJECTIVE: To study the association between reduced use of postnatal steroids for bronchopulmonary dysplasia (BPD) in very low birthweight (VLBW) infants and oxygen (O(2))-dependency at 28 days of age and at 36 weeks postmenstrual age.
DESIGN: Large national database study.
SETTING: The Israel National VLBW Neonatal Database. PATIENTS: The sample included infants born between 1997 and 2004, of gestational age 24-32 weeks, who required mechanical ventilation or O(2) therapy. Four time periods were compared: 1997-8 (era 1, peak use), 1999-2000 (era 2, intermediate), 2001-2 (era 3, expected reduction) and 2003-4 (era 4, lowest). The outcome variable "oxygen dependency" was based on clinical criteria. Multivariate regression models were used to account for confounding variables.
RESULTS: Steroid use fell significantly from 23.5% in 1997-8 to 11% in 2003-4 (p<0.005). After adjustment for relevant confounding variables, the odds ratio for O(2) therapy at 28 days in era 4 versus era 1 was 1.75, 95% confidence interval (CI) 1.47 to 2.09 and 1.41, 95% CI 1.15 to 1.73 at 36 weeks postmenstrual age. The mean duration of O(2) therapy increased from 25.3 days (95% CI 23.3 to 26.3) in era 1, to 28.0 days (95% CI 26.6 to 29.4) in era 4. Survival increased from 78.5% in era 1 to 81.6% in era 4 (p<0.005).
CONCLUSIONS: The use of steroids has fallen considerably since the awareness of the adverse effects of this treatment. This change has been temporally associated with increased O(2) dependency at 28 days of age and at 36 weeks postmenstrual age. The prolongation of O(2) therapy was modest in degree.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16769711      PMCID: PMC2675295          DOI: 10.1136/adc.2006.094474

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  25 in total

1.  Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.

Authors: 
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

2.  Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial.

Authors:  Lex W Doyle; Peter G Davis; Colin J Morley; Andy McPhee; John B Carlin
Journal:  Pediatrics       Date:  2006-01       Impact factor: 7.124

3.  Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  A R Stark; W A Carlo; J E Tyson; L A Papile; L L Wright; S Shankaran; E F Donovan; W Oh; C R Bauer; S Saha; W K Poole; B J Stoll
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

4.  A randomized trial of moderately early low-dose dexamethasone therapy in very low birth weight infants: dynamic pulmonary mechanics, oxygenation, and ventilation.

Authors:  Manuel Durand; Maria E Mendoza; Phuket Tantivit; Amir Kugelman; Cindy McEvoy
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

5.  Impaired glucocorticoid synthesis in premature infants developing chronic lung disease.

Authors:  K L Watterberg; J S Gerdes; K L Cook
Journal:  Pediatr Res       Date:  2001-08       Impact factor: 3.756

6.  Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants.

Authors:  K L Watterberg; J S Gerdes; K L Gifford; H M Lin
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

Review 7.  The effect of postnatal steroids on growth and development.

Authors:  H L Halliday
Journal:  J Perinat Med       Date:  2001       Impact factor: 1.901

8.  alpha1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial.

Authors:  J A Stiskal; M S Dunn; A T Shennan; K K O'Brien; E N Kelly; R I Koppel; D W Cox; S Ito; S L Chappel; M Rabinovitch
Journal:  Pediatrics       Date:  1998-01       Impact factor: 7.124

9.  Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase.

Authors:  Jonathan M Davis; Richard B Parad; Theresa Michele; Elizabeth Allred; Anita Price; Warren Rosenfeld
Journal:  Pediatrics       Date:  2003-03       Impact factor: 7.124

10.  Excess risk of mortality in very low birthweight triplets: a national, population based study.

Authors:  E S Shinwell; I Blickstein; A Lusky; B Reichman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

View more
  8 in total

Review 1.  Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Wes Onland; Anne Pmc De Jaegere; Martin Offringa; Anton van Kaam
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

Review 2.  Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?

Authors:  Eric C Eichenwald; Ann R Stark
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-09       Impact factor: 5.747

Review 3.  Targeting inflammation to prevent bronchopulmonary dysplasia: can new insights be translated into therapies?

Authors:  Clyde J Wright; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-06-06       Impact factor: 7.124

4.  A comparison of Wisconsin neonatal intensive care units with national data on outcomes and practices.

Authors:  Erika W Hagen; Mona Sadek-Badawi; Aggie Albanese; Mari Palta
Journal:  WMJ       Date:  2008-11

5.  Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants.

Authors:  Deanne Wilson-Costello; Michele C Walsh; John C Langer; Ronnie Guillet; Abbot R Laptook; Barbara J Stoll; Seetha Shankaran; Neil N Finer; Krisa P Van Meurs; William A Engle; Abhik Das
Journal:  Pediatrics       Date:  2009-02-09       Impact factor: 7.124

6.  Postnatal corticosteroids for bronchopulmonary dysplasia.

Authors:  Alan H Jobe
Journal:  Clin Perinatol       Date:  2009-03       Impact factor: 3.430

7.  Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.

Authors:  Wes Onland; Martin Offringa; Filip Cools; Anne P De Jaegere; Karin Rademaker; Henry Blom; Eric Cavatorta; Anne Debeer; Peter H Dijk; Arno F van Heijst; Boris W Kramer; Andre A Kroon; Thilo Mohns; Henrica L van Straaten; Arjan B te Pas; Claire Theyskens; Mirjam M van Weissenbruch; Anton H van Kaam
Journal:  BMC Pediatr       Date:  2011-11-09       Impact factor: 2.125

8.  Evidence-Based Neonatal Unit Practices and Determinants of Postnatal Corticosteroid-Use in Preterm Births below 30 Weeks GA in Europe. A Population-Based Cohort Study.

Authors:  Alexandra Nuytten; Hélène Behal; Alain Duhamel; Pierre-Henri Jarreau; Jan Mazela; David Milligan; Ludwig Gortner; Aurélie Piedvache; Jennifer Zeitlin; Patrick Truffert
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.